Volume | 778,922 |
|
|||||
News | - | ||||||
Day High | 0.5448 | Low High |
|||||
Day Low | 0.51 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
BioVie Inc | BIVI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.5336 | 0.51 | 0.5448 | 0.5286 | 0.5336 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,202 | 778,922 | $ 0.5318769 | $ 414,291 | - | 0.4812 - 8.9699 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:54:41 | formt | 3,850 | $ 0.5286 | USD |
BioVie Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
21.13M | 39.87M | - | 0 | -50.26M | -1.26 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BioVie News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BIVI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.6255 | 0.6255 | 0.4812 | 0.5523379 | 1,381,769 | -0.0969 | -15.49% |
1 Month | 1.26 | 3.31 | 0.4812 | 1.51 | 7,137,999 | -0.7314 | -58.05% |
3 Months | 1.33 | 3.31 | 0.4812 | 1.49 | 2,598,717 | -0.8014 | -60.26% |
6 Months | 3.13 | 5.82 | 0.4812 | 1.82 | 1,609,814 | -2.60 | -83.11% |
1 Year | 8.55 | 8.9699 | 0.4812 | 2.24 | 920,869 | -8.02 | -93.82% |
3 Years | 18.44 | 23.86 | 0.4812 | 4.00 | 489,353 | -17.91 | -97.13% |
5 Years | 10.50 | 46.0977 | 0.4812 | 4.48 | 426,821 | -9.97 | -94.97% |
BioVie Description
BioVie Inc is a company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is currently focused on developing and commercializing BIV201, a novel investigational approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism. |